Overview

A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer

Status:
Completed

Trial end date:
2018-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability of three intratumoral injections of VCN-01 combined with Abraxane®/gemcitabine, and to determine the recommended phase II dose of VCN-01 combined with Abraxane®/gemcitabine.

Phase:

Phase 1

Details

Lead Sponsor:

VCN Biosciences, S.L.

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel